Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31499Editorial articleПередовая статьяReview ArticleMetabolic syndrome and coronary heart diseaseМетаболический синдром и ишемическая болезнь сердцаGurgenianS VГургенянС Вgoorggenyan@mail.ruVatinianS KhВатинянС Хmarsjurist@rambler.ruZelveianP AЗелвеянП Аzelveian@hotmail.comНИИ кардиологии им. Л. Оганесяна, Ереван, АрменияНациональный институт здравоохранения Армении15032014863VOL 86, NO3 ()ТОМ 86, №3 (2014)10611010042020Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31499

The literature review presents current views on micro- and macrovascular disorders in metabolic syndrome characterized by silent myocardial ischemia detectable only during exercise and myocardial radionuclide scintigraphy.

Аннотация. В обзоре литературе представлены современные взгляды на проблему микро- и макрососудистых нарушений при метаболическом синдроме, для которого характерно развитие "немой" ишемии миокарда, выявляемой только при физической нагрузке и радионуклидной сцинтиграфии миокарда.

micro- and macrovascular disordersendothelial dysfunctionsilent myocardial infarctionмикро- и макрососудистые нарушениядисфункция эндотелия"немая" ишемия миокардаMcNeill A.M., Rosamond W.D., Girman C.J. et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol 2004; 94: 1249-1254.International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Accessed March 13, 2006.Yusuf S., Hawken S., Ounpuu S. et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.Saely C., Aczel S., Marte T. et al. The Metabolic Syndrome, Insulin Resistance, and Cardiovascular Risk in Diabetic and Nondiabetic Patients. J Clin Endocrin Metabol 2005; 90: 5698-5703.Kannel W.B. Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110: 1100-1107.Pen A., Yam Y., Chen L. et al. Discordance between Framingham Risk Score and atherosclerotic plaque burden. Eur Heart J 2013; 34: 1075-1082.Montecucco F., Vuilleumier N., Pagano S. et al. Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 412-421.Nigro J., Osman N., Dart A. et al. Insulin Resistance and Atherosclerosis. Endocrine Rev 2006; 27 (3): 242-259.Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.Williams K., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-561.Williams K., Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol J 1998; 9: 471-474.Skalen K., Gustafsson M., Rydberg E. et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-754.Witztum J.H. The oxidative hypotheses of atherosclerosis. Lancet 1994; 344: 793-795.Blankenberg S., Barbaux S., Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.Roganec K.S., Ulrich C., Blomer L. et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J 2010; 31: 369-376.Fortuno A., Jose G., Moreno M. et al. Oxidative stress and vascular remodeling. Exp Physiol 1997; 6: 305-311.Zeiher A., Drexler H., Wollschlager H. et al. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984-1992.Mogenson C.E. Hypertension and diabetes. Lippincott Williams & Wilkins. 2002.Prior J., Quiñones M., Hernandez-Pampaloni M. et al. Coronary Circulatory Dysfunction in Insulin Resistance, Impaired Glucose Tolerance, and Type 2 Diabetes Mellitus. Circulation 2005; 111: 2291-2298.Шевченко О.П., Праскурничий Е.А., Шевченко А.О. Метаболический синдром. М: Реафарм 2004.Mondorf U., Russ A., Wiesemann A. et al. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. J Hypertens 1998; 11: 174-183.Georgiou I., Elisaf M., Siamopoulos K. et al. Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome. J Renin Angiotensin Aldosterone Syst 2007; 8: 181.Weiss D., Kools J., Taylor W. Angiotensin II-induced hypertension acceleration the development of atherosclerosis in apoE-deficient mice. Circulation 2001; 103: 448-454.Golden S. Prevention of coronary heart disease in metabolic syndrome and diabetes mellitus. Advanced Studies in Pharmacy 2002; 2: 364-371.Mykkanen L., Kuusisto J., Pyorala K. Cardiovascular disease risk factors as predictors of type 2 (non-insulin dependent) diabetes mellitus in elderly subjects. Diabetologia 1993; 36: 553-559.Deedwania P. Metabolic Syndrome and Vascular Disease. Is Nature or Nurture Leading the New Epidemic of Cardiovascular Disease? Circulation 2004; 109: 2-4.Assmann G., Schulte G. The Prospective Cardiovascular Munster study prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am J Cardiol 1987; 59: 9G-17G.Assmann G., Schulte G. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713-1724.Assmann G., Schulte G. Relation high density lipoprotein cholesterol and triglicerides tj incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733-737.Трубецкой А.В. Регуляция коронарного кровообращения. Руководство по кардиологии. Под ред. Е.И. Чазова. М: Медицина 1982; 240-248.Selye H. The stress of life. New York: McGraw-Hill 1975.Хехт А. Введение в экспериментальные основы современной патологии сердечной мышцы. М: Медицина 1975.Shea T.M., Watson R.M.., Piotrowski S.F. et al. Anaerobic myocardial metabolism. Am J Physiol 1962; 203: 463-469.Després J.P., Lemieux I., Dagenais G.R. et al. HDL-cholesterol is a marker of coronary heart disease in the Quebec Cardiovascular Study. Atherosclerosis 2000; 153: 263-272.Dale A., Nilsen T., Vatten L. et al. Diabetes mellitus and risk of fatal ischeamic heart disease by gender: 18-year follow-up of 94914 individuals in the HUNT 1 Study. Eur Heart J 2007; 28: 2924-2929.Stanley W., Ryden L. The Diabetic Coronary Patient. London: Science Press Ltd 1999.Efstratopoulos V.S., Hatzis G.T., Mougros B.A. Left ventricular hypertrophy аnd coronary heart disease in patients with metabolic syndrome and arterial hypertension. Hippokratia 2004; 8: 69-72.Dale A., Midtcjell K., Nilsen T. et al. Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the NUNT Study in Norway. Eur Heart J 2009; 30: 1372-1377.Barnes E., Camici P. Diagnosis of heart disease in diabetes: new insights into myocardial insulin resistance. In: The Diabetic Coronary Patient. London: Science Press Ltd 1999.Galderisi M., Cicala S., Caso P. et al. Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am J Cardiol 2002; 90: 860-864.Ammar R., Dellsperger K. Соronary artery disease in diabetes. In: The diabetic coronary patient. London: Science Press Ltd 1999.Niaura R., Todaro J., Stroud L. et al. Hostility, the metabolic syndrome, and incident coronary heart disease. Health Psychol 2002; 21: 588-593.Butler K.R., Macdonald T.M., Strutners A.D. et al. The clinical implication of diabetic heart disease. Eur Heart J 1998; 19: 1617-1627.Dortimer A., Shenoy P., Shiroff R. Diffuse coronary disease in diabetics; fact or fiction? Circulation 1978; 57: 133-136.Butler K.R. Hemoglobin levels, cardiovascular disease, and left ventricular hypertrophy in patients with chronic kidney disease. Case study of the anemic patient. Nephrol Nurs J 2002; 29: 189.Burgess D.C., Hunt D., Li L. Incidence and predictions of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 2011; 31: 92-99.Herlitz J., Malmberg K., Karlson B. et at. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarctions. Acta Med Scand 1988; 224: 31-38.Sundstrom J. Left ventricular hypertrophy and the insulin resistance syndrome. Acta Universitatis Upsaliensis 2001; 992: 68.Mouguet F., Cuileret F., Susen S. et al. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: associated with hyperglycemia/insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J 2009; 30: 840-849.Shehadeh A., Regan T. Cardiac consequences of diabetes mellitus. Clin Cardiol 1995; 18: 301-305.Iwasaka T., Takahashi N., Nakamura S. et al. Residual left ventricular pump dysfunction after acute myocardial infarction in NIDDM patients. Diab Care 1992; 15: 1522-1526.